<SEC-DOCUMENT>0001129928-20-000024-index.html : 20200508 <SEC-HEADER>0001129928-20-000024.hdr.sgml : 20200508 <ACCEPTANCE-DATETIME>20200508090008 ACCESSION NUMBER: 0001129928-20-000024 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 6 CONFORMED PERIOD OF REPORT: 20200331 FILED AS OF DATE: 20200508 DATE AS OF CHANGE: 20200508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ONCOLYTICS BIOTECH INC CENTRAL INDEX KEY: 0001129928 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38512 FILM NUMBER: 20858916 BUSINESS ADDRESS: STREET 1: 1167 KENSINGTON CRES NW SUITE 210 STREET 2: CALGARY ALBERTA CANADA T2N 1X7 CITY: ALBERTA CANADA STATE: A0 ZIP: 00000 BUSINESS PHONE: 4036707380 MAIL ADDRESS: STREET 1: 210 - 1167 KENSINGTON CRES NW CITY: CALGARY STATE: A0 ZIP: T2N 1X7 </SEC-HEADER> <DOCUMENT> <TYPE>6-K <SEQUENCE>1 <FILENAME>q12020form6-k.htm <DESCRIPTION>2020 FIRST QUARTER 6-K <TEXT> Document 1 - file: q12020form6-k.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-99.1 <SEQUENCE>2 <FILENAME>ex991-interimfsmar312020.htm <DESCRIPTION>2020 FIRST QUARTER INTERIM FINANCIAL STATEMENTS <TEXT> Document 2 - file: ex991-interimfsmar312020.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-99.2 <SEQUENCE>3 <FILENAME>ex992-q12020mda.htm <DESCRIPTION>2020 FIRST QUARTER MD&A <TEXT> Document 3 - file: ex992-q12020mda.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-99.3 <SEQUENCE>4 <FILENAME>ex993-q12020certificationx.htm <DESCRIPTION>Q1 2020 CERTIFICATION CEO <TEXT> Document 4 - file: ex993-q12020certificationx.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-99.4 <SEQUENCE>5 <FILENAME>ex994-q12020certificationx.htm <DESCRIPTION>Q1 2020 CERTIFICATION CFO <TEXT> Document 5 - file: ex994-q12020certificationx.htm
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>6 <FILENAME>oncolyticslogotaglinebluea06.jpg <TEXT> Document 6 - file: oncolyticslogotaglinebluea06.jpg
</DOCUMENT> </SEC-DOCUMENT>